Transition Therapeutics announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company. Read the full story

Eli Lilly and Bristol-Myers Squibb announced that the companies have agreed to transfer rights to Erbitux (cetuximab) in North America Read the full story

Eli Lilly and Hanmi Pharmaceutical have entered into an exclusive license and collaboration agreement for the development and commercialization of Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224 Read the full story

Cerecor has acquired exclusive, worldwide rights from Eli Lilly to develop and commercialize LY2456302 Read the full story

Bristol-Myers Squibb and Eli Lilly announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib Read the full story

Eli, Lilly and Company pharma partners on a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affects about 95 percent of those with the disease. Read the full story

Eli Lilly and Adocia announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro Read the full story

Eli Lilly and Company, Anthem, Inc. and HealthCore pharma partners for a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. Read the full story